Table 2.
Univariate and multivariate analysis of prognostic factors in patients (PFS)
| Parameters | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|
| Median (months) | 95% CI | HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age | ||||||||
| ≤ 65 | 9.9 | 7.8–12.0 | 0.95 | 0.54–1.66 | 0.862 | |||
| > 65 | 8.1 | 1.2–15.0 | ||||||
| Sex | ||||||||
| Male | 11.6 | 7.2–16.1 | 0.66 | 0.37–1.16 | 0.15 | |||
| Female | 6.7 | 3.2–10.2 | ||||||
| Smoking statusa | ||||||||
| Smoker | 14.8 | 10.1–19.5 | 0.54 | 0.25–1.16 | 0.113 | |||
| Never smoker | 8.1 | 5.5–10.6 | ||||||
| Performance status, PS | ||||||||
| PS 2 | 9.9 | 8.4–11.4 | 0.94 | 0.52–1.69 | 0.826 | |||
| PS 3/4 | 6.2 | 5.0–7.5 | ||||||
| Mutation | 0.446 | |||||||
| L858R | 8.4 | 5.2–11.5 | 0.77 | 0.33–1.80 | 0.548 | |||
| 19del | 10.2 | 7.3–13.1 | 0.59 | 0.25–1.41 | 0.235 | |||
| Uncommon | 3.5 | 0.5–6.6 | ||||||
| Starting dose | ||||||||
| 40 mg | 10.8 | 8.6–13.1 | 0.55 | 0.31–0.98 | 0.043 | 0.92 | 0.49–1.75 | 0.806 |
| 30 mg | 6.7 | 1.9–11.5 | ||||||
| Metastatic sites | ||||||||
| Lung | ||||||||
| Yes | 8.1 | 5.5–10.6 | 1.41 | 0.81–2.46 | 0.222 | |||
| No | 9.9 | 8.5–11.3 | ||||||
| Liver | ||||||||
| Yes | 3.1 | 0.0–13.3 | 1.94 | 1.02–3.69 | 0.044 | 2.17 | 1.11–4.26 | 0.023 |
| No | 9.9 | 6.5–13.3 | ||||||
| Brain | ||||||||
| Yes | 9.8 | 7.6–12.0 | 1.16 | 0.66–2.04 | 0.615 | |||
| No | 8.6 | 5.8–11.5 | ||||||
| Bone | ||||||||
| Yes | 9.8 | 8.1–11.5 | 0.65 | 0.38–1.14 | 0.133 | |||
| No | 5.9 | 1.4–10.2 | ||||||
| Pleura | ||||||||
| Yes | 8.1 | 0.8–15.3 | 1.92 | 1.07–3.45 | 0.03 | 1.58 | 0.84–2.98 | 0.157 |
| No | 10.2 | 6.8–13.6 | ||||||
| Adrenal gland | ||||||||
| Yes | 8.6 | 0.0–21.1 | 1.13 | 0.35–3.64 | 0.842 | |||
| No | 8.9 | 5.4–12.3 | ||||||
| Distant lymphadenopathy | ||||||||
| Yes | 6.7 | 0.0–15.9 | 1.91 | 0.74–4.94 | 0.183 | |||
| No | 8.9 | 7.0–10.8 | ||||||
| Dose reduction/interruption | ||||||||
| Yes | 11.6 | 9.0–14.3 | 0.65 | 0.36–1.16 | 0.143 | |||
| No | 6.2 | 0. 0–12.7 | ||||||
| Discontinuation, AE-related | ||||||||
| Yes | 6.7 | 0.6–12.8 | 0.64 | 0.20–2.07 | 0.457 | |||
| No | 8.9 | 6.9–10.8 | ||||||
| Clinical tumor response | < 0.001 | < 0.001 | ||||||
| CR/PR | 11.8 | 9.2–14.4 | 0.05 | 0.02–0.13 | < 0.001 | 0.05 | 0.02–0.13 | < 0.001 |
| SD | 18.4 | 4.7–32.1 | 0.04 | 0.01–0.14 | < 0.001 | 0.05 | 0.01–0.19 | < 0.001 |
| PD/NA | 1.4 | 0.9–1.8 | ||||||
| BMI | 1.05 | 0.97–1.13 | 0.244 | |||||
| BSA | 0.1 | 0.01–2.02 | 0.132 | |||||
IQR interquartile range, CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not assessed, HR hazard ratio, CI confidence interval, BMI body mass index, BSA body surface area, PFS progression-free survival, AE adverse events
aThere is one missing data point on smoking status